Synthorx Competitors, Revenue, Alternatives and Pricing

Claim your profile

Overview

Location:
Total Funding:$165.7M
Industry:Biotech
Founded:2014
Lead Investor(s):OrbiMed

Industry Ranking

Estimated Revenue & Financials

  • Synthorx's estimated annual revenue is currently $3.3M per year.
  • Synthorx received $63.0M in venture funding in May 2018.
  • Synthorx's estimated revenue per employee is $72,333
  • Synthorx's total funding is $165.7M.

Employee Data

  • Synthorx has 45 Employees.
  • Synthorx grew their employee count by -4% last year.
  • Synthorx currently has 1 job openings.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingOnline ReviewPricing
DiaCarta
$7M4510%N/A-N/A
Geron Corporati...
N/A205N/AN/A-N/A
Rigel Pharmaceu...
$46.8M3024%N/A-N/A
Althea Technolo...
$22.3M144N/AN/A-N/A
INOVA Diagnosti...
$44.3M286N/AN/A-N/A
10X Genomics
$101.2M65346%N/A-N/A
ProTrials Resea...
$33.3M2153%N/A-N/A
Advanced Cell D...
$28.7M1858%N/A-N/A
The J. Craig Ve...
$39.4M254N/AN/A-N/A
CellMax Life
$6.5M4214%N/A-N/A
Missing a competitor? Contribute!?
Submit

Synthorx Inc. is a biotechnology company using synthetic biology to discover and develop novel protein therapeutics. Synthorx's expanded genetic alphabet platform has the unique ability to drive the site-specific incorporation of multiple synthetic amino acids into proteins thereby tuning receptor specificity important for improving efficacy and safety. In addition, their engineered organisms provide the ability to manufacture these improved proteins, called Synthorins, with the required fidelity and yield. The unique Synthorx platform expands the chemical and structural repertoire of protein therapeutics and uncovers new ways to modulate pharmacological properties of biologics, not possible with other technologies. The company was founded based on important discoveries in Dr. Floyd Romesberg's lab at The Scripps Research Institute in conjunction with Avalon Ventures, which housed Synthorx in its incubator, COI Pharmaceuticals, Inc. The company is headquartered in La Jolla, Calif.

keywords:Biotechnology,Healthcare,Pharmaceuticals

45

Number of Employees

$3.3M

Revenue (est)

1

Current Jobs

-4%

Employee Growth %

$165.7M

Total Funding

N/A

Valuation

N/A

Accelerator

B2C

Type

Synthorx News

09/03/2019 - Synthorx to Present at HC Wainwright 21st Annual Global ...

SAN DIEGO, Aug. 29, 2019 (GLOBE NEWSWIRE) -- Synthorx, Inc. (THOR), a clinical-stage biotechnology company developing optimized ...

08/12/2019 - Scripps bigshot who cofounded Synthorx exits amid mystery

Floyd Romesberg, Ph.D., the renowned Scripps Research scientist and scientific founder of synthetic cytokine biotech Synthorx, has bid the ...

09/03/2019 - Synthorx (NASDAQ:THOR) Upgraded to Buy by ValuEngine

ValuEngine upgraded shares of Synthorx (NASDAQ:THOR) from a hold rating to a buy rating in a research report sent to investors on Thursday, ...

Synthorx Funding

DateAmountRoundLead InvestorsReference
2014-05-09$UndisclosedUndisclosedAvalon VenturesArticle
2014-06-10$3.1MUndisclosedArticle
2016-07-20$10.0MBRA Capital ManagementArticle
2018-05-01$63.0MCOrbiMedArticle

Synthorx Executive Hires

DateNameTitleReference
2016-11-29Patrick DoyleChief Business OfficerArticle
2017-08-15Marcos MillaSenior Vice President of ResearchArticle
2017-11-28Laura ShawverPresident/CEOArticle
2018-07-13Enoch KariukiSVP Corporate DevelopmentArticle
2018-08-17Joseph LevequeChief Medical OfficerArticle